^
    Back
    Association details:
    Biomarker:FGFR1 mutation
    Cancer:Solid Tumor
    Drug:Lytgobi (futibatinib) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Efficacy and safety of futibatinib for refractory advanced solid malignancies with FGFR alterations identified in circulating tumor DNA: TiFFANY, A GOZILA-affiliated Trial.

    Published date:
    05/25/2023
    Excerpt:
    Futibatinib demonstrated promising efficacy in refractory advanced solid malignancies with FGFR alterations in ctDNA with an acceptable toxicity profile. Oncogenic co-alterations detected by ctDNA genotyping may predict primary resistance.
    DOI:
    10.1200/JCO.2023.41.16_suppl.3102